DIA: Driving Insights to Action
Science:Life Sciences
New drugs are getting through the FDA approval process faster. According to a study published in January 2020, the review time for standard drug applications has decreased from more than 36 months in 1983 to approximately ten months in 2018. “It can be a good thing for drugs to reach the market faster, if those drugs offer large benefits. But often drugs offer only very small benefits over existing treatments,” says Dr. Jonathan Darrow, pharmaceutical policy expert and Assistant Professor at Harvard Medical School in Boston. “The system we have is a patchwork of various policies,” explains Dr. Joshua Sharfstein, former FDA Principal Deputy Commissioner, now Vice Dean and Professor at Johns Hopkins Bloomberg School of Public Health in Baltimore. “We should take a step back and say, ‘Are there ways to align incentives more so we have more money to spend for treatments that make a huge difference for people who need them?’”
DIAmond Session 203: “Innovation is Clearly Happening”: Next Generation Collaboration: Transforming the Industry
DIAmond Session 201: International Regulatory Convergence, Collaboration & Cooperation
Executive FDA Leadership Reviews & Previews PDUFA Reauthorization
“Biosimilars have at last come of age in the United States”
Mission, History & Opportunity Attracts New DIA Americas Leadership
Clinical & Real-World Data: Is AI the Missing Link?
TransCelerate Moves Clinical QMS from Vision to Conceptual Framework
Executive Director Shares New CTTI Strategic Plan to Improve Clinical Trials
Who Determines the Price of Medicines – and How?
“An Urgent Imperative Now to Learn Quickly”: DIA 2016 Co-Chair Dr. Gigi Hirsch
Industry-Patient Relations: Culture Change or Culture Shock?
Every Journey Begins with a First Step: DIA Patient Engagement
“Outbreaks are inevitable. Pandemics are preventable.” – DIA 2016 Keynote Speaker Dr. Larry Brilliant
Growing Irrelevancy of Pre- versus Post-Market Divide for EU Medical Devices
Crossroads in Europe: Access from a Market and HTA Perspective
A Visionary Takes the Helm at DIA Europe, Middle East & Africa (DIA EMEA)
Steps to Meet the “Big Quality” Challenge of “Big Data”
Innovation: Can it Span the “Efficacy versus Effectiveness Gap”?
Dr. Kemal Malik Ponders “Is Innovation Always the Answer?”
EMA Senior Medical Officer Explains “Access versus Evidence Tradeoff”
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Speaking of Psychology